SIRT7 inhibitor 97491, a potent SIRT7 inhibitor with an IC 50 of 325 nM, reduces deacetylase activity of SIRT7 in a dose-dependent manner. SIRT7 inhibitor 97491 prevents tumor progression by increasing p53 stability through acetylation at K373/382. SIRT7 inhibitor 97491 promotes apoptosis through caspase pathway. In Vitro SIRT7 inhibitor 97491 (1-10 μM) reduces cell growth in MES-SA cells, without causing cytotoxicity in HEK293 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: Human uterine sarcoma MES-SA cells Concentration: 1, 5, 10 μM Incubation Time: 72 hours Result: Led to more than 50% decrease in cell proliferation at concentrations of 5 and 10 μM. Cell Cytotoxicity AssayCell Line: Human embryonic kidney cell line HEK293 cells Concentration: 1, 5, 10 μM Incubation Time: 24 hours Result: HEK293 cells were almost unaffected. In Vivo SIRT7 inhibitor 97491 (2 mg/kg; intraperitoneally injected; for 3 weeks, except on weekends) inhibits tumor growth in xenograft mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Balb/c nude mice (18-20 g; 6-8 weeks old) with MES-SA cells Dosage: 2 mg/kg Administration: Intraperitoneally injected; for 3 weeks, except on weekends. Result: Inhibited cancer growth in vivo. Form:Solid IC50& Target:SIRT7 325 nM (IC 50 )